In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Carlyle Expands Device Venture Finance Group

Executive Summary

When most industry people hear of The Carlyle Group, they think of it exclusively as a buyout group, and indeed leveraged buyouts are an important part of the global private equity firm's business. But many are surprised to learn that Carlyle has a venture and growth capital operation that maintains a strong commitment to investing in the medical device sector.

You may also be interested in...



What Do Device Investors Want?

Perhaps the question most often posed by entrepreneurs and start-up company executives is, "What are device investors looking for these days?" At Windhover's recent IN3 West conference, industry leaders provided several different perspectives on that question. In this article, we excerpt portions of a discussion that featured two prominent organizations with long-term commitments to medical device investing, but which operate from different points on the investor spectrum: Medtronic Inc. and the Carlyle Group.

What Do Device Investors Want?

Perhaps the question most often posed by entrepreneurs and start-up company executives is, "What are device investors looking for these days?" At Windhover's recent IN3 West conference, industry leaders provided several different perspectives on that question. In this article, we excerpt portions of a discussion that featured two prominent organizations with long-term commitments to medical device investing, but which operate from different points on the investor spectrum: Medtronic Inc. and the Carlyle Group.

Proteus Biomedical: Using Computers to Manage Chronic Diseases

Modeled after advanced computers used in industrial applications, such as automotives, Proteus Biomedical hopes to bring what it calls pervasive computing to treat chronic conditions such as chronic heart failure and, later on, others. The company's approach combines device and drug therapy in an innovative kind of combination products; in the process, says Proteus, it will define not just a new category of medical products but also shape a new competitive landscape.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel